Currently, the only approved combination therapy of immunotherapy and antiangiogenic approach for NSCLC is the PD-L1 inhibitor atezolizumab in combination with bevacizumab, paclitaxel, and carboplatin for the first-line treatment of patients with metastatic non-squamous NSCLC with no EGFR or ALK genomic tumor aberrations.506 AK112, a tetrameric bispecific antibody targeting PD-1 and VEGF, has shown in a phase I dose-escalation study with a manageable safety profile.507 It is currently being evaluated in a phase II clinical trial for stage IIIB/C or IV NSCLC (NCT04736823). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.